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Several 2-(N-substituted carboxamidomethylthio)-5-
(4-acetylaminophenyl)-1,3,4-oxadiazoles 4 a-s have been
synthesized and tested for their Jl]ltibacterial, anti-
tubercular, anticancer and anti-HfV activities. The
structures of these compounds have been established on
the basis of elemental analysis and spectral data.
In continuation of our project for the synthesis
of new anti-HIV and anticancer agents, we
report herein the synthesis of 2,5-disubstituted-
1,3,4-oxadiazoles.
N-Acetyl derivative 1 of benzocaine was pre-
pared by refluxing benzocaine with acetic anhy-
dride and acetic acid. It was converted into 4-
acetylaminophenyl hydrazide 2 on treatment with
hydrazine hydrate in ethanol. 2 was converted into
5-(4-acetylaminophenyl)-1 ,3,4-oxadiazole-2-thione
3 by refluxing with CS2 in alcoholic solution of
potassium hydroxide. 3 was treated with different




The compounds 4 a-s were screened against
E. coli, S. aureus and Salmonella typhi Para A by
cup plate method". As compared to the standard
drug chloromycetin, these compounds showed
moderate activity. Compound 4n showed excellent
activity against S. aureus which is better than even
the standard drug (Table I).
Tuberculostatic activity




















zoles were tested for their tuberculostatic activity
against H37Rv strain of Mycobacterium tuber-
culosis using Lowenstein-1ensen's egg medium by
serial two fold dilution method". Compounds 4
c,d, 4 g,b, 4 n,o and 4 z showed activity at lower
concentration (30 ug/ml.), while compounds 4 b-d,
4 f, 4 h, 4 j, 4 m-q, showed activity at higher
concentration (100 ug/ml.) which is moderate as
compared to Rephampicin (Table-I).
Anti-AIDS (HIV - 1) activity
The synthesized compounds have been screened
for their anti-AIDS (HIV-l) activity which
involved susceptible human host cells (CEM cell
line) II. The compounds were tested over a wide
range of concentration of which results of
NOTES ISI
Table I-Characterization data and antimicrobial activity of 4.-1(inhibition zone in mm)
S.No. Ar Mol. fonnula· m.p. Antibacterial activity Antitubercular activity··
°C E. coliod S. aureus S. typhi 30 100
para A J,lglmL J,lglmL
4. C,Hs C.1H.6O)N.S 205 20 16 17
4b 2-CI-C6H. C.sHuO)N.SCI 170 20 16 17 +
4c 3-C1-C6H. C.1HUO)N.SCI 120 17 14 15 + +
4d 4-C1-C6H. C.sH.sO)N.SCI 165 20 17 16 + +
ok 2-N02-C6H. C.IHuOsNsS 172 17 15 15
4r 3-N02-C6H. C.IHuOsNsS 187 18 17 15 +
4C 4-N02-C6H. C.IHuOsNsS 157 20 15 16 +
•••• 2-OC2Hs-C6H • C20H20O.N.S 170 20 15 17 + +4. 4-OC2Hs-C6H. C20H20O.N.S 188 18 16 22
4j 4-Br-C6H. C ••H.1O)N.SBr 182 18 IS 20 +
4k 3-CH)-C6H. C.9H.1O)N.S 152 11 14 20
41 4-CH)-C6H. C.9H.8O)N.S \38 18 17 22
4m 2-OCH)-C6H. C.9H.1O.N.S 162 17 22 18 +
4. 3-OCH)-C6H. C.9H.1O.N.S 198 17 30 21 + +
40 4-OCH)-C6H. C.9H.1O.N.S 175 17 15 20 + +
4p 2,4-(Clh-C6H) C.sH1.O)N.SCI2 152 17 20 20 +
4q 2,4-(CH)h-'C6H) C2oH20O)N.S 185 20 15 18 + +
4r 2-N02-4-CI-C6H) C.sH ••OsNsSCI 159 18 22 17
45 2-C1-4-N02-C6H) C.1H •.osNsSCI 174 20 20 17
• All compounds gave satisfactory C, H, N, S and halogen analysis .
•• ( + ) Indicates Active and ( - ) Indicates Inactive.
maximum activity and corresponding concentration
are given in Table II.
Anticancer activity
The synthesized compounds were screened for
their anticancer activity". Each compound was
tested at five different concentrations against 60
cell lines of nine types of human cancers namely
leukemia, lung, colon, CNS, melanoma, ovarian,
renal, prostate and breast cancers. Results are
expressed as log.oGI5o which is the drug
concentration (M) causing a 50 % reduction in the
net protein increase in control cells during the drug
incubation. The results of anticancer activity are
shown in Table II.
Experimental
Preparation of 4-carbethoxyacetanilide. Ben-
zocaine (16.5 g, 0.1 mole), acetic anhydride
(12 ml., 0.15 mole) and g1. acetic acid (30 mL)
were refluxed for 4 hr. Excess solvent was
removed by distillation and the residual mixture
was poured over crushed ice. The white crystals
separated out, which were recrystallised from
ethanol (95%), yield 82%, m.p. 107°C [N, 6.72
(Cal. N, 6.70%)].
Preparation of 4-acetylaminophenyl hydra-
zide. A mixture of 4-carbethoxyacetanilide (20.7 g,
0.1 mole), hydrazine hydrate (20 mL, 0.4 mole)
and absolute alcohol (50 mL) was refluxed for 12
hr. Excess solvent was distilled off. The reaction
mixture was cooled to 4-50 C and solid crystals that
separated were filtered, washed with cold water,
dried and recrystallised from ethanol, yield 78 %,
m.p. 2780C[N ,21.78% (Cat. N, 2l.75%)].
Preparation of 5-(4-acetylaminopbenyl)-l,3,4-
oxadiazole-2-thione. 4-Acetylaminophenyl hydra-
zide (19.3 g, 0.1 mole) was dissolved in aq.
solution of potassium hydroxide (5.6 g, 0.1 mole)
with constant stirring. The mixture was added to
methanol (100 mL) to get clear solution. CS2 (6
mL, 0.1 mole) was then added and the mixture
refluxed for 6hr. It was concentrated on a water-
bath. The resulting solution was poured on ice
water and filtered. The filtrate was acidified with
dilute hydrochloric acid. The product thus obtained
was filtered, washed with cold water and dried in
oven at 105° C. It was recrystallised from ethanol,
yield, 65%, m.p. ,250°C (Found: N, 17.85; S,
13.60. C
1S
HI60)N4S requires N,17.81; S, 13.62 %).
Preparation of 2-(N-carboxamidomethyl-
thio )-5-(4-acetylaminophenyl)-1, 3, 4-oxadiazole.
5-(4-Acetylaminophenyl)-1, 3, 4-oxadiazole-2-
thione (2.35 g, 0.01 mole) was dissolved in
aqueous solution of potassium hydroxide (lOg) in
100 mL water. a-Chloroacetanilide (2.37 g, 0.014
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Table II Anti-HI V and anticancer activity of synthesized compounds 4
S. Ar Anti-HlV activity Anticancer activity % Growth
No retardation
Infected Uninfe. Dose Type- Cell line Gl6QxIO·!5
Res. Res Molar
4. C6HS 10.21 096.14 3.50 x 10.7 D HCT-116 \.66 93
F LOX 1MVI \.96 82
B NCI-H-522M \.69 70
4g 4-N02-C6H4 10.50 092.57 3.80 x 10.
7 D HCT-116 2.58 100
F LOX IMVI 1.06 99
C DMS-273 1.(i5 97
H RXF-393 1.96 94
4f 3-N02-C6H4 10.15 067.16 5.50 x 10.
7 No retardation
4e 2-N02-C6H4 0970 110.06 2.00 x 10.
6 No retardation
4m 2-0CH3-C6H4 11.44 030.87 3.90 x 10.
4 No retardation
4k 3-CHrC6H4 09.83 098.78 6.90 x 10'~ No retardation
41 4-CH3-C6H4 10.09 10\.54 8.90 x 10.7 No retardation
40 3-OCH3-C6H4 Not screened E U-25 I \.70 100
D KM-20 L2 1.69 100
H UO-31 1.85 98
40 4-OCH3-C6H4 Not screened Repeat testing at primary stage
4p 2,4-(CIh-C6HJ Not screened D HCT-116 2.20 88
F MALME3M \.64 64
H SNI2C 2.40 50
4b 2-CI-C6H4 Not screened No retardation
4c 3-CI-C6H4 Not screened No retardation
4d 4-CI-C6H4 Not screened No retardation
• Type of cancer B = non small cell lung cancer, C = small cell lung cancer, D = colon cancer, E = CNS cancer, F = melanoma,
H = renal cancer.
mole) was added slowly within 2 hr at 80° C. The
contents were left overnight. The solid crystals
were filtered, washed with cold water, dried and
recrystallized form ethanol, yield 48%, m.p.
205oC, [N, 12.44% (Cat. 12.42%), S, 7.10% (Cat.
S, 7.14%)]. IR (KBr) : 3275 (-N-H str.), 1650
(-CO-NH), 1600 (>C=N- str.), 1520 (-C-O-C),
1400 (-S-CH2), 1360 (-C-H), 1280 (=N-N=C str.),
840 cm-) (sub. benzene). 'HMR: 8 9.3(-NH), 6.8 -
7.4 (m, 9H, ArH), 2.9 (s, 2H, -CH
2
-), 2.3 (s, 3H, -
CHJ
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